Tumor Dosimetry and Response for 153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
UNLABELLED: (153)Sm-ethylenediamine tetramethylene phosphonic acid ((153)Sm-EDTMP) therapy for osteosarcoma is being investigated. In this study, we analyzed the influence of (153)Sm-EDTMP administered activity (AA), osteosarcoma tumor density, mass, and the shape of the tumor on absorbed dose (AD). We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response. METHODS: Nineteen tumors in 6 patients with recurrent, refractory osteosarcoma enrolled in a phase I or II clinical trial of (153)Sm-EDTMP were analyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package. Patients received a low dose of (153)Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic recovery by a second, high dose (222 MBq/kg). Treatment response was evaluated using either CT or MRI after each therapy. SPECT/CT of the tumor regions were obtained at 4 and 48 h or 72 h after (153)Sm-EDTMP therapy for 3D-RD analysis. Mean tumor AD was also calculated using the OLINDA/EXM unit-density sphere model and was compared with the 3D-RD estimates. RESULTS: On average, a 5-fold increase in the AA led to a 4-fold increase in the mean tumor AD over the high- versus low-dose-treated patients. The range of mean tumor AD and equivalent uniform dose (EUD) for low-dose therapy were 1.48-14.6 and 0.98-3.90 Gy, respectively. Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respectively. Mean tumor AD estimates obtained from OLINDA/EXM were within 5% of the mean AD values obtained using 3D-RD. On an individual tumor basis, both mean AD and EUD were positively related to percentage tumor volume reduction (P = 0.031 and 0.023, respectively). CONCLUSION: The variations in tumor density, mass, and shape seen in these tumors did not affect the mean tumor AD estimation significantly. The tumor EUD was approximately 2- and 3-fold lower than the mean AD for low- and high-dose therapy, respectively. A dose-response relationship was observed for transient tumor volume shrinkage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552 · cited 1×
“The Kenward–Roger approximation was used to assess the degrees of freedom (20).”
MethodProton‐based radiotherapy for unresectable or incompletely resected osteosarcoma
Ciernik, I. F., Niemierko, A., Harmon, D. C., Kobayashi, W., Chen, Y., Yock, T. I., Ebb, D. H., Choy, E., Raskin, K. A., Liebsch, N., et al. (2011) · Cancer · doi:10.1002/cncr.26037 · Cited by 191 · cited 1×
“3-y) tumor control in this patient population (27).”
BackgroundHobbs, R. F., McNutt, T., Baechler, S., He, B., Esaias, C. E., Frey, E. C., Loeb, D. M., Wahl, R. L., Shokek, O., & Sgouros, G. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.022 · Cited by 53
Self-citation
Cited by
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Self-citationKainz, W., Neufeld, E., Bolch, W. E., Graff, C. G., Kim, C. H., Kuster, N., Lloyd, B., Morrison, T., Segars, P., Yeom, Y. S., et al. (2019) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2018.2883437 · Cited by 109
“[120] who explored tumor dosimetry and response for 153Sm-EDTMP (Quadramet) therapy in patients with high-risk osteosarcoma.”
The Role of Preclinical Models in Radiopharmaceutical Therapy
Sgouros, G., Hobbs, R. F., & Abou, D. S. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e121 · Cited by 16
Self-citationPlyku, D., Loeb, D. M., Prideaux, A. R., Baechler, S., Wahl, R. L., Sgouros, G., & Hobbs, R. F. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1803 · Cited by 10
“A comparison between two-dimensional and three-dimensional dosimetric results (previously published 34 ) for a set of same tumors and a comparison of the differences in the relative uncertainties estimated in phantoms 11,36 are also undertaken with this objec-tive in mind.”
InfluentialSelf-citation
Metadata
- Authors
- Senthamizhchelvan, S., Hobbs, R. F., Song, H., Frey, E. C., Zhang, Z., Armour, E., Wahl, R. L., Loeb, D. M., & Sgouros, G.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2012-01-17
- Volume
- 53
- Issue
- 2
- Pages
- 215-224
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2143020447
- Cited by
- 41
- References
- 3
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Dosimetry and Response for 153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma. https://app.cochat.ai/papers/10.2967/jnumed.111.096677
- The paper
- Senthamizhchelvan, S., Hobbs, R. F., Song, H., Frey, E. C., Zhang, Z., Armour, E., Wahl, R. L., Loeb, D. M., & Sgouros, G. (2012). Tumor Dosimetry and Response for 153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.111.096677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.